(Bupivacaine + meloxicam) ER is a Small Molecule owned by Heron Therapeutics, and is involved in 19 clinical trials, of which 14 were completed, 3 are ongoing, and 2 are planned.

Bupivacaine is a PGE (2) receptor antagonist and sodium channel blocker. Meloxicam is a cyclo-oxygenase 2 inhibitor. Bupivacaine binds to sodium channels (1,2,3,4,5,8,9,10) and blocks sodium influx into nerve cells. Voltage gated sodium channels are essential for generation and conduction of electrical impulses in excitable cells. Prostaglandin E (2) receptors implicated in several physiologic responses which potentiate the pain responses.

Meloxicam is an oxicam derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Meloxicam inhibits the activity of cyclo-oxygenase (COX-I and COX-II), resulting in a decreased conversion of arachidonic acid into prostaglandin precursors. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of meloxicam.

The revenue for (Bupivacaine + meloxicam) ER is expected to reach a total of $4.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Bupivacaine + meloxicam) ER NPV Report.

(Bupivacaine + meloxicam) ER is currently owned by Heron Therapeutics.

(Bupivacaine + meloxicam) ER Overview

Bupivacaine and Meloxicam (Zynrelef) is a fixed dose combination developed based on Biochronomer technology. It is formulated as extended release wound solution for intralesional and periarticular route of administration. Zynrelef is indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty and indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Bupivacaine in combination with meloxicam (HTX-011, HTX-011-19)  is under development for the treatment of postoperative pain in hallux valgus (Bunion). The drug candidate is administered through subcutaneous route. the drug candidate is developed as extended release formulation. Bupivacaine belongs to amino amide group that targets sodium channel and prostaglandin E (2) receptor. Meloxicam is an analgesic which targets cyclo-oxygenase (COX-I and COX-II).

Heron Therapeutics Overview

Heron Therapeutics (Heron) is a biotechnology company that uses proprietary polymer-based drug delivery platform to develop novel, patient-focused drugs for patients suffering from various types of cancer and pain. Its proprietary Biochronomer technology is a polymer-based drug delivery platform, which improves the therapeutic profile of injectable pharmaceuticals. The company’s marketed products include Sustol, an extended-release injection indicated in combination with other antiemetics in adults for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy (MEC); Cinvanti for chemotherapy-induced nausea and vomiting (CINV) prevention and Zynrelef (HTX-011) for the treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults. Heron is headquartered in San Diego, California, the US.

The company reported revenues of (US Dollars) US$86.4 million for the fiscal year ended December 2021 (FY2021), a decrease of 2.6% over FY2020. The operating loss of the company was US$217.8 million in FY2021, compared to an operating loss of US$228.2 million in FY2020. The net loss of the company was US$220.7 million in FY2021, compared to a net loss of US$227.3 million in FY2020. The company reported revenues of US$27.6 million for the second quarter ended June 2022, an increase of 17.8% over the previous quarter.

Quick View – (Bupivacaine + meloxicam) ER

Report Segments
  • Innovator (Non-NME)
Drug Name
  • (Bupivacaine + meloxicam) ER
Administration Pathway
  • Intralesional
  • Periarticular
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.